Skip to main content
CHE $532.88 -0.80%
CHE logo

CHE · Chemed Corp

Track CHE — free
$532.88 -4.29 (-0.80%) At close · Aug 14
Market Cap
$6.96B
Shares
13.07M
All earnings calls

Earnings call · FY2026 Q2

Chemed Corp Q2 FY2026 Earnings Call

Chemed Corp Q2 FY2026 Earnings Call

Concluded Jul 29, 2026 Audio replay
Jul 29, 2026 42:47 34 turns
Period
FY2026 Q2
Runtime
42:47
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Chemed reported Q2 2026 consolidated revenue up 8.8% to $673.3 million and adjusted diluted EPS up 41.9% to $6.06, driven primarily by VITAS outperformance, and raised full-year guidance. VITAS admissions grew 9.0% and no Florida Medicare cap billing limitation is anticipated for 2026, while Roto-Rooter margin declined 77 basis points on elevated marketing costs.

VITAS hospice admissions growth 31 Florida Medicare cap position 24 Roto-Rooter commercial business 23 VITAS M&A and CON moratorium 11 Roto-Rooter franchise acquisitions 10 Roto-Rooter marketing and lead generation costs 10

Management tone

Confident

Net tone +62 · low hedging

Grounding quotes
  • “VTAS' performance during the quarter exceeded even the high end of our expectations.”
  • “This strong performance makes us more confident than ever that VTAS has put the Florida cap issue of 2025 behind us and has returned to a normalized rate of growth.”
  • “Roto-Rooter is building positive operating momentum while being in a great position to take advantage of franchise acquisition opportunities as they arise.”
  • “lead generation and the resulting cost of customer acquisition remained a challenge in the second quarter.”

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $673.25M +8.8% YoY
Diluted EPS $5.13 +43.7% YoY
Net income $67.70M +29% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Full-year guidance increased, primarily due to VITAS outperformance
  • VITAS admissions grew 9.0% to 19,125 in Q2 2026
  • VITAS adjusted EBITDA excluding Medicare cap grew 20.6% to $80.6 million with margin up 196 bps to 18.2%
  • No Florida Medicare cap billing limitation recorded in Q2 2026 and none anticipated for full-year 2026
  • Consolidated revenue increased 8.8% and adjusted diluted EPS increased 41.9% to $6.06

Risks & pressure points

  • Roto-Rooter adjusted EBITDA was essentially flat and margin declined 77 bps to 21.1%
  • Free Internet leads declined 13.1% and paid lead share rose to ~59%, increasing marketing spend by about $3.1 million
  • Roto-Rooter EBITDA missed internal point estimate by roughly $1 million on marketing costs

Key moments

Jump directly to management's words in the synchronized transcript.

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Segment Vitas$443.34M +11.9% YoY
Segment Roto Rooter$229.91M +3.3% YoY

Capital returned

Buybacks · derived
$97.48M
Shares repurchased
210,000
Dividend / share
$0.70
Full-screen source Call document